ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen: FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

DOW JONES NEWSWIRES Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones. According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem. "We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development. Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million. A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful. Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months. Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
12/02/201616:00:00Amgen Announces Launch Of Blood Counts™ And Collaboration With S...
12/02/201609:00:00Amgen And Allergan Submit Biosimilar Marketing Authorization...
12/01/201616:00:00Amgen To Present At The Citi 2016 Global Healthcare Conference
11/30/201618:31:00The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv...
11/30/201618:30:00The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv...
11/30/201610:00:00Amgen Announces Presentation Of New Data In Acute Lymphoblastic...
11/16/201616:30:00Amgen Announces Erenumab Significantly Reduces Monthly Migraine...
11/15/201616:00:00Amgen And Allergan Submit Biosimilar Biologics License Application...
11/15/201612:28:00Repatha® (Evolocumab) Regresses Atherosclerosis In Patients...
11/14/201609:00:00New 'Ten To Watch' List Highlights Top Amgen Scholars Poised...
11/12/201616:30:00Results From Phase 3 BRIDGE Study Show Romosozumab Significantly...
11/11/201616:00:00European Commission Approves Parsabiv™ (etelcalcetide) For T...
11/10/201616:00:00Amgen To Webcast Investor Meeting At Upcoming American Heart...
11/10/201608:33:00Amgen Announces Collaboration With Janssen To Co-Fund Studies...
11/07/201616:00:00Data To Be Presented At ACR/ARHP 2016 Annual Meeting Show Amgen's...
11/04/201617:26:00FDA Approves Expanded Use Of ENBREL® (etanercept) To Treat Children...
11/04/201608:50:00Regeneron Revenue Growth Slows
11/03/201617:25:27Statement of Changes in Beneficial Ownership (4)
11/03/201616:01:00Amgen To Present At The Credit Suisse 25th Annual Healthcare...
11/02/201609:00:00Amgen Appoints Lori Johnston As Senior Vice President, Human...

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US